Thank you, Pablo.
current confined inhibitors are Our challenges needed. There limitations checkpoint class a alone who The or respond increase modalities becoming to in induce types and to immunotherapy patients only inhibitors and a to responses of immunotherapy portion immunotherapy tumors in new one are revolutionized of are rate antitumor duration and increasingly treatment. to two, to existing tumor cured. patients and checkpoint of other immunologically in cold Responses are refractory as activity small cancer options. are and evident are the approaches certain
cellular to adaptive which that expresses we system. the effective generate of broadly designed the therapy the the allogeneic To normal RTX-XXX, the immune in response. of arms X-XBB antitumor the and stimulate mimics immune hundreds of these RTX-XXX of thousands of an IL-XX in communication engineered surface, copies and an on innate presentation ligand cell system cell-cell signals and end,
These T has in that inhibitors. immunotherapy to RTX-XXX cells approach refractory as act synergistically to resulting provides and tumor believe as both cell and a or potentially activation treat two natural naïve proliferation cells, and NK or well cells We cells leading killing. to checkpoint disease killer differentiated including whose on key patients patients immunotherapies, become signals transformative in resistant
for in cleared IND been FDA. tumors RTX-XXX solid As mentioned, has the by Pablo the
clinical are been process announce dosed well patient X the clinical of trial the in trial. Phase the sites we We into initiating has first to currently plan when our and
immunotherapies. plan combination we escalation, with PD-X in a inhibitor other evaluate monotherapy Following RTX-XXX and dose to
are to AML. tumors, thus cells the solid The to cell cytotoxic RTX-XXX leukemia to dysfunction acute decreasing myeloid resulting cells, to potential. addition In NK disease patients we known plan in thought AML. to progression and in NK differentiation evaluate inhibit their or with contribute is function of AML
to induces Furthermore, of NK and of studies, cell cells preclinical the treatment and AML. evaluation during setting of in function after both NK is the observed it proliferation both And the activation underscoring to clinical setting. cells has been our refractory therapy also or relapsed that in linked RTX-XXX response role NK supporting this the
to the setting could be data NK where the transplant trial, generated could been RTX-XXX leukemia contribute Once the initial the of graft the effect transplant. versus in safety population have X in Phase evaluated post-hematopoietic
We at AML later expect a date. the to timing program provide of an update the on
immunotherapy goal and the antitumor tumors activity to resistance program both in in Ultimately, malignancies. and improve to overcome patients with development the solid is hematologic RTX-XXX clinical
antigen. to to artificial approach target second antigen XX I’d of modalities cell human In different specific antigen vivo. turn broad endogenous T activate particular a system a therapeutic contrast while number under immune this RTX-XXX like case, targets and oncology, the cells program. to RTX-XXX papillomavirus a now our presenting development RTX-XXX, stimulation, HPV to that our are or expand in XX, first in In
HPV We in cell bound these ligand address in and To-date, along approaches HPV X-XBB developed class cancers. efficacy. induced antigen expresses clinical an have peptide To on this the which X, with MHC surface. RTX-XXX, need had IL-XX general to limited
killing As When therapeutic. and cell the in our a tumor RTX-XXX shown activity, of three signals we red these promotes and have PBMC. specific with studies expressed human cell in T of cytolytic surface production simultaneously cells. antigen resulting cytokine delivered preclinical expansion, on are
surrogate are using Importantly, mirroring mRBC-XXX RCT.
have surrogate in spreading only to mirroring tumor preclinical broader response. as We models. able the to generate immune epitope well, Thus, is RCT evidence but antigen effective antitumor target means induce response preliminary a antitumor immunity selected to an immune Epitope our mirroring that additional are spreading. the to we creating able not of antigens
annual We the at We data via next the at had to plan or conference. AACR planned month these data meeting to these meeting. share another rescheduled present
they because two key including RTX-XXX specific data CAR-T preclinical these immunotherapies about excited suggest may therapy. very other antigen are We cell limitations of address
trial activates First, loss antigens RTX-XXX therapies This tumor RTX-XXX. multiple significantly has and would Efforts response this where clinical immune trial. mechanism treated the in resistance be patients through been epitope in anticipated tumor define and against not in our our antigen a expands in to tumor the will periphery CAR-T loss studies major in mechanism. seek both an to X to the contrast antigen is in Therefore, spreading a resistance translational spreading. epitope the and response Phase
thus effectively than control patients to CAR-T. cell relapsed more effector and which better Current expected specific stimulation that and offer tumor-specific induces options of refractory is with T and including be may RTX-XXX with tolerability observed limited. treatment we to expect better the tolerability. cancers have has able therapy potent therapies cells Second, to highly for are And immune a HPV-driven expansion that
an by for to RTX-XXX file XXXX. IND the end plan We of
stimulate long-term patients. T for treatment immune distinct oncology broadly two improve both a antigen the in and induce cells tumor-specific approaches may change Taken through landscape the system our specific the dramatically to and together, immune response cancer outlook
our would like Chief to call to Dr. turn Larry programs. now provide over Scientific an the update Officer to Turka, autoimmune I on Larry?
